Tenax Therapeutics (TENX) Earning Somewhat Positive Media Coverage, Analysis Shows
Press coverage about Tenax Therapeutics (NASDAQ:TENX) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tenax Therapeutics earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 45.6257847066352 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of NASDAQ:TENX traded up $0.11 during mid-day trading on Tuesday, hitting $5.64. The company had a trading volume of 8,100 shares, compared to its average volume of 141,210. Tenax Therapeutics has a one year low of $4.40 and a one year high of $12.63.
Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Tuesday, August 14th. The specialty pharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.29). analysts forecast that Tenax Therapeutics will post -5.85 EPS for the current fiscal year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Featured Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.